Erenumab Dose 3
Sponsors
Amgen
Conditions
Migraine
Phase 3
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
CompletedNCT03832998
Start: 2019-09-05End: 2026-01-07Updated: 2026-01-20
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Active, not recruitingNCT03836040
Start: 2019-07-19End: 2026-11-19Updated: 2026-07-16